Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H14O3 |
| Molecular Weight | 278.302 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3C=CC=C4C
InChI
InChIKey=HARGZZNYNSYSGJ-JTQLQIEISA-N
InChI=1S/C18H14O3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-7,10H,8H2,1-2H3/t10-/m0/s1
| Molecular Formula | C18H14O3 |
| Molecular Weight | 278.302 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Dihydrotanshinone I (DHI), a diterpenoid first isolated from the roots of Salvia miltiorrhiza, is a relatively high affinity inhibitor of human AChE. Dihydrotanshinone I (10 and 25 mg/kg) significantly attenuates atherosclerotic plaque formation, alteres serum lipid profile, decreases oxidative stress and shrinks necrotic core areas in ApoE-/- mice. Dihydrotanshinone I dramatically inhibits the enhanced expression of LOX-1, NOX4, and NF-κB in aorta. Dihydrotanshinone I treatment can improve cardiac function, reduce infarct size, ameliorate the variations in myocardial zymogram and histopathological disorders, decrease 20-HETE generation, and regulate apoptosis-related protein in myocardial ischemia-reperfusion rats.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24900610 |
0.6 µM [Ki] | ||
Target ID: CHEMBL6023 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27389501 |
|||
Target ID: CHEMBL1743319 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28466663 |
0.72 µM [IC50] | ||
Target ID: map04210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26547530 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The cardioprotection of dihydrotanshinone I against myocardial ischemia-reperfusion injury via inhibition of arachidonic acid ω-hydroxylase. | 2016-12 |
|
| Dihydrotanshinone I Attenuates Atherosclerosis in ApoE-Deficient Mice: Role of NOX4/NF-κB Mediated Lectin-Like Oxidized LDL Receptor-1 (LOX-1) of the Endothelium. | 2016 |
|
| Structures of human acetylcholinesterase bound to dihydrotanshinone I and territrem B show peripheral site flexibility. | 2013-11-14 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27891092
Curator's Comment: Mice were dosed daily via intragastric gavage
Mice: Dihydrotanshinone I (10 and 25 mg/kg) significantly attenuates atherosclerotic plaque formation, alteres serum lipid profile, decreases oxidative stress and shrinks necrotic core areas in ApoE-/- mice.
Route of Administration:
Intragastric
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27891092
In lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs), Dihydrotanshinone I (10 nM) decreased lectin-like ox-LDL receptor-1 (LOX-1) and NADPH oxidase 4 (NOX4) expression, reactive oxygen species (ROS) production, NF-κB nuclear translocation, ox-LDL endocytosis and monocytes adhesion.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 10:24:36 GMT 2025
by
admin
on
Wed Apr 02 10:24:36 GMT 2025
|
| Record UNII |
562G9360V6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8105
Created by
admin on Wed Apr 02 10:24:36 GMT 2025 , Edited by admin on Wed Apr 02 10:24:36 GMT 2025
|
PRIMARY | |||
|
Dihydrotanshinone I
Created by
admin on Wed Apr 02 10:24:36 GMT 2025 , Edited by admin on Wed Apr 02 10:24:36 GMT 2025
|
PRIMARY | |||
|
87205-99-0
Created by
admin on Wed Apr 02 10:24:36 GMT 2025 , Edited by admin on Wed Apr 02 10:24:36 GMT 2025
|
PRIMARY | |||
|
11425923
Created by
admin on Wed Apr 02 10:24:36 GMT 2025 , Edited by admin on Wed Apr 02 10:24:36 GMT 2025
|
PRIMARY | |||
|
DTXSID20236187
Created by
admin on Wed Apr 02 10:24:36 GMT 2025 , Edited by admin on Wed Apr 02 10:24:36 GMT 2025
|
PRIMARY | |||
|
562G9360V6
Created by
admin on Wed Apr 02 10:24:36 GMT 2025 , Edited by admin on Wed Apr 02 10:24:36 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |